| Kim D Bennett, DO | |
|
252 Rural Acres Dr, Beckley, WV 25801-3503 | |
| (304) 252-8551 | |
| (304) 252-1790 |
| Full Name | Kim D Bennett |
|---|---|
| Gender | Male |
| Speciality | Pediatrics |
| Location | 252 Rural Acres Dr, Beckley, West Virginia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295827814 | NPI | - | NPPES |
| 3004166000 | Medicaid | WV | |
| H90133 | Other | HEALTH NET | |
| 2145382 | Other | UNITEDHEALTHCARE | |
| 321488 | Other | CARELINK | |
| 54878 | Medicaid | WV | |
| 58941 | Medicaid | WV |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 1988 (West Virginia) | Primary |
| Entity Name | Community Health Systems Inc |
|---|---|
| Entity Type | Part B Supplier - Public Health/welfare Agency |
| Entity Identifiers | NPI Number: 1588738538 PECOS PAC ID: 6608785795 Enrollment ID: O20040311000504 |
News Archive
Galenea Corp. has been awarded a highly competitive grant from the National Institute of Mental Health in response to the solicitation "Recovery Act Limited Competition: NIH Director's Opportunity for Research in Five Thematic Areas (RC4)," funded by the American Recovery and Reinvestment Act of 2009. Galenea has developed an innovative technology platform, termed MANTRA™ (Multiwell, Automated NeuroTRansmission Assay) that enables high-throughput screening for the identification of small molecule modulators of synaptic transmission.
Researchers from Mount Sinai School of Medicine have developed a new computational method that will help streamline the analysis of gene expression experiments and provide scientists with a better mechanistic understanding of the differences between diseased and normal cells. The new database and software, called ChIP Enrichment Analysis (ChEA), will revolutionize how researchers identify drug targets and biomarkers.
Lymphatic vessels exposed to fast-flowing blood take on characteristics associated with blood vessels, report researchers.
Idera Pharmaceuticals, Inc., today announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt, Germany. The milestone was achieved upon initiation of a Phase 2 trial by Merck KGaA of EMD 1201081, a novel agonist of Toll-like Receptor 9 (TLR9), in combination with cetuximab (Erbitux®) in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kim D Bennett, DO 252 Rural Acres Dr, Beckley, WV 25801-3503 Ph: (304) 252-8551 | Kim D Bennett, DO 252 Rural Acres Dr, Beckley, WV 25801-3503 Ph: (304) 252-8551 |
News Archive
Galenea Corp. has been awarded a highly competitive grant from the National Institute of Mental Health in response to the solicitation "Recovery Act Limited Competition: NIH Director's Opportunity for Research in Five Thematic Areas (RC4)," funded by the American Recovery and Reinvestment Act of 2009. Galenea has developed an innovative technology platform, termed MANTRA™ (Multiwell, Automated NeuroTRansmission Assay) that enables high-throughput screening for the identification of small molecule modulators of synaptic transmission.
Researchers from Mount Sinai School of Medicine have developed a new computational method that will help streamline the analysis of gene expression experiments and provide scientists with a better mechanistic understanding of the differences between diseased and normal cells. The new database and software, called ChIP Enrichment Analysis (ChEA), will revolutionize how researchers identify drug targets and biomarkers.
Lymphatic vessels exposed to fast-flowing blood take on characteristics associated with blood vessels, report researchers.
Idera Pharmaceuticals, Inc., today announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt, Germany. The milestone was achieved upon initiation of a Phase 2 trial by Merck KGaA of EMD 1201081, a novel agonist of Toll-like Receptor 9 (TLR9), in combination with cetuximab (Erbitux®) in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
› Verified 5 days ago
Carlos Estanislao Lucero, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 403 Carriage Drive, Beckley, WV 25801 Phone: 304-255-7456 Fax: 304-255-5899 | |
Dr. Petaiah Mohan, M.D Pediatrics Medicare: Medicare Enrolled Practice Location: 194 Carriage Dr, Beckley, WV 25801 Phone: 304-255-6051 Fax: 304-255-6051 | |
Ramon Lacanilao, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 30 Mallard Court, Beckley, WV 25801 Phone: 304-255-0800 Fax: 304-255-1040 | |
Dr. Michele Dawn Staton, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 2401 S Kanawha St, Suite 110a, Beckley, WV 25801 Phone: 304-929-4646 Fax: 304-929-4649 | |
Dr. Malik Hamdan, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 1710 Harper Rd, Beckley, WV 25801 Phone: 304-256-4100 Fax: 304-254-3016 | |
Dr. Saraswathi Mohan, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 194 Carriage Dr, Beckley, WV 25801 Phone: 304-255-6051 Fax: 304-255-6051 |